1. Scrip
  2. >>Business

Lupin's Generic Spiriva Launch Delayed As FDA Action Expected By August

Medisol Acquisition To Push Injectables Growth

 
• By Vibha Ravi

Lupin has pushed the launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables

FDA Approval Stamp
Lupin Awaits FDA Action On A Spiriva Generic • Source: Shutterstock

Lupin Limited is now hopeful of a September launch for its generic to Boehringer Ingelheim GmbH’s chronic obstructive pulmonary disease blockbuster drug Spiriva (tiotropium bromide) as it expects the US Food and Drug Administration (FDA)’s Target Action Date (TAD) latest by August.

The company had earlier received a Complete Response Letter (CRL) from the agency regarding its Abbreviated New Drug Application (ANDA) and has been responding to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.